Circulating des-acyl ghrelin improves cardiovascular risk prediction in older hypertensive patients

American Journal of Hypertension

Volumn 27, Issue 5, 2014, Pages 727-733

  Yano, Yuichiro ^a   Nakazato, Masamitsu ^b   Toshinai, Koji ^b   Inokuchi, Takashi ^c   Matsuda, Shuntaro ^b   Hidaka, Toshiaki ^d   Hayakawa, Manabu ^b   Kangawa, Kenji ^e   Shimada, Kazuyuki ^a   Kario, Kazuomi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c Department of Orthopaedics Chikamorikai Medical Group Kochi   (Japan)

^d Kitaura National Health Insurance Hospital   (Japan)

^e NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

blood pressure; cardiovascular disease; des acyl ghrelin; geriatric; hypertension.

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DES ACYL GHRELIN; GHRELIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG; ADIPOQ PROTEIN, HUMAN; GHRELIN, DES-N-OCTANOYL; SERPINE1 PROTEIN, HUMAN;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; PRIORITY JOURNAL; SMOKING; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; AGE; BLOOD; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; EPIDEMIOLOGY; INCIDENCE; JAPAN; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; VERY ELDERLY;

ADIPONECTIN; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; FEMALE; GHRELIN; HUMANS; HYPERTENSION; INCIDENCE; JAPAN; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84898853184     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt232     Document Type: Article

References (34)

1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656-660.
2. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S. A role for ghrelin in the central regulation of feeding. Nature 2001; 409:194-198.
3. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005; 85:495-522.
4. Mak RH, Cheung WW. Is ghrelin a biomarker for mortality in end-stage renal disease? Kidney Int 2011; 79:697-699.
5. Tesauro M, Schinzari F, Iantorno M, Rizza S, Melina D, Lauro D, Cardillo C. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 2005; 112:2986-2992.
6. Kleinz MJ, Maguire JJ, Skepper JN, Davenport AP. Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man. Cardiovasc Res 2006; 69:227-235.
7. Tesauro M, Schinzari F, Rovella V, Di Daniele N, Lauro D, Mores N, Veneziani A, Cardillo C. Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome. Hypertension 2009; 54:995-1000.
8. Lambert E, Lambert G, Ika-Sari C, Dawood T, Lee K, Chopra R, Straznicky N, Eikelis N, Drew S, Tilbrook A, Dixon J, Esler M, Schlaich M P. Ghrelin modulates sympathetic nervous system activity and stress response in lean and overweight men. Hypertension 2011; 58:43-50.
9. Yano Y, Toshinai K, Inokuchi T, Kangawa K, Shimada K, Kario K, Nakazato M. Plasma des-acyl ghrelin, but not plasma HMW adiponec-tin, is a useful cardiometabolic marker for predicting atherosclerosis in elderly hypertensive patients. Atherosclerosis 2009; 204:590-594.
10. Carrero JJ, Nakashima A, Qureshi AR, Lindholm B, Heimbürger O, Bárány P, Stenvinkel P. Protein-energy wasting modifes the association of ghrelin with infammation, leptin, and mortality in hemodialysis patients. Kidney Int 2011; 79:749-756.
11. Chou CC, Bai CH, Tsai SC, Wu MS. Low serum acylated ghrelin levels are associated with the development of cardiovascular disease in hemo-dialysis patients. Intern Med 2010; 49:2057-2064.
12. Wassertheil-Smoller S, Fann C, Allman RM, Black HR, Camel GH, Davis B, Masaki K, Pressel S, Prineas RJ, Stamler J, Vogt TM. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Te SHEP Cooperative Research Group. Arch Intern Med 2000; 160:494-500.
13. Aflalo J, Karunananthan S, Eisenberg MJ, Alexander K P, Bergman H. Role of frailty in patients with cardiovascular disease. Am J Cardiol 2009; 103:1616-1621.
14. Yano Y, Hoshide S, Tamaki N, Inokuchi T, Nagata M, Yokota N, Hidaka T, Kanemaru Y, Matsuda S, Kuwabara M, Shimada K, Kario K. Regional diferences in hypertensive cardiovascular remodeling between fshing and farming communities in Japan. Am J Hypertens 2011; 24:437-443.
15. Yano Y, Bakris GL, Inokuchi T, Ohba Y, Tamaki N, Nagata M, Kuwabara M. Yokota N, Eto T, Kuroki M, Shimada K, Kario K. Association of cognitive dysfunction with cardiovascular disease events in elderly hypertensive patients. J Hypertens, in press.
16. Akamizu T, Shinomiya T, Irako T, Fukunaga M, Nakai Y, Nakai Y, Kangawa K. Separate measurement of plasma levels of acylated and desacyl ghrelin in healthy subjects using a new direct ELISA assay. J Clin Endocrinol Metab 2005; 90:6-9.
17. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58:1072-1083.
18. Roger B. Newson. Comparing the predictive powers of survival models using Harrell's C or Somers' D. Stata J 2010;10:339-358.
19. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115:928-935.
20. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Tird report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) fnal report. Circulation 2002; 106:3143-3421.
21. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassifcation and beyond. Stat Med 2008; 27:157-172.
22. Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation 2010; 121:1768-1777.
23. Kishimoto I, Tokudome T, Hosoda H, Miyazato M, Kangawa K. Ghrelin and cardiovascular diseases. J Cardiol 2012; 59:8-13.
24. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, patho-physiology, and pharmacology. Pharmacol Rev 1991; 43:109-142.
25. Chuang JC, Zigman JM. Ghrelin's roles in stress, mood, and anxiety regulation. Int J Pept 2010; 2010:460549.
26. Inelmen EM, Sergi G, Coin A, Miotto F, Peruzza S, Enzi G. Can obesity be a risk factor in elderly people? Obes Rev 2003; 4:147-155.
27. Kizer JR, Benkeser D, Arnold AM, Mukamal KJ, Ix JH, Zieman SJ, Siscovick DS, Tracy R P, Mantzoros CS, Deflippi CR, Newman AB, Djousse L. Associations of total and high-molecular-weight adiponec-tin with all-cause and cardiovascular mortality in older persons: the Cardiovascular Health Study. Circulation 2012; 126:2951-2961.
28. Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 2007; 167:1510-1517.
29. Wannamethee SG, Welsh P, Lowe GD, Gudnason V, Di Angelantonio E, Lennon L, Rumley A, Whincup PH, Sattar N. N-terminal pro-brain natriuretic Peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without pre-existing cardiovascular disease. J Am Coll Cardiol 2011; 58:56-64.
30. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293:1609-1616.
31. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue infam-mation and metabolic syndrome. Mol Cell Endocrinol 2010; 314:1-16.
32. Hozawa A, Sugawara Y, Tomata Y, Kakizaki M, Tsuboya T, Ohmori-Matsuda K, Nakaya N, Kuriyama S, Fukao A, Tsuji I. Relationship between serum adiponectin levels and disability-free survival among community-dwelling elderly individuals: the Tsurugaya Project. J Gerontol A Biol Sci Med Sci 2012; 67:530-536.
33. Yano Y, Hoshide S, Ishikawa J, Noguchi C, Tukui D, Takanori H, Tada M, Kanemaru Y, Yano A, Ishikawa S, Shimada K, Kario K. Te diferen-tial efects of angiotensin II type 1 receptor blockers on microalbumi-nuria in relation to low-grade infammation in metabolic hypertensive patients. Am J Hypertens 2007; 20:565-572.
34. Ohashi K, Ouchi N, Matsuzawa Y. Adiponectin and hypertension. Am J Hypertens 2011; 24:263-269.